

Egypt Pharmaceutical Market By Type {Pharmaceutical Drugs (Gynecology Drugs, Respiratory Drugs, Dermatology Drugs, Analgesic Drugs, Oncology Drugs, Others) and Biologics), By Biologics (Monoclonal Antibodies (MAbS, Therapeutic Proteins, Vaccines)}, By Drug Classification (Branded Drugs v/s Generic Drugs), By Mode of Purchase (Prescription-Based Drugs v/s Over-the-counter Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, Competition, Forecast and Opportunities, 2028F

<https://marketpublishers.com/r/ECEB51BF6D50EN.html>

Date: August 2023

Pages: 76

Price: US\$ 3,500.00 (Single User License)

ID: ECEB51BF6D50EN

Abstracts

Egypt Pharmaceutical Market is expected to grow at a significant rate during the forecast period. One of the main factors influencing the market is the rising demand for pharmaceuticals during the COVID-19 pandemic in order to supply patients with enough medications. Additionally, the government is heavily funding research and development (R&D) projects that enable quick drug discovery for bettering health outcomes. The industry is being positively impacted by this as well as the growing proficiency of leading market participants in specialty pharmaceuticals including innovative biologics and biosimilars, complicated generics, and preventive medicine. Additionally, the increasing use of intelligent automation in the pharmaceutical sector for disease diagnosis and management is fueling market expansion. Furthermore, the creation of a single-window system to speed up the approval of economically viable projects and expedite the drug development process is boosting demand for pharmaceuticals in the nation. Moreover, growing investments in long-term, high-risk projects by different funding outlets are

providing industry investors with profitable growth chances.

The Egyptian pharmaceutical market is driven by a number of factors, including the country's large population, increasing healthcare spending, and rising demand for healthcare products and services. The government has also been investing heavily in the healthcare sector in recent years, which has led to an increase in the availability and accessibility of healthcare products and services across the country. The most commonly prescribed therapeutic categories in Egypt are cardiovascular, gastrointestinal, and anti-infective drugs. The country also has a significant demand for generics and over-the-counter (OTC) medications.

Egypt's pharmaceutical industry is dominated by domestic manufacturers, which account for over 70% of the market share. The remaining market share is held by multinational pharmaceutical companies. The top domestic pharmaceutical companies in Egypt include Amoun Pharmaceutical Company, EIPICO, and Memphis Pharmaceutical and Chemical Industries.

In terms of regulations, the Egyptian Ministry of Health and Population is responsible for regulating the pharmaceutical industry in the country. The ministry has implemented a number of reforms in recent years aimed at improving the regulatory environment and promoting investment in the sector.

Overall, the pharmaceutical market in Egypt is expected to continue to grow in the coming years, driven by increasing demand for healthcare products and services, rising healthcare spending, and government investment in the sector.

Adoption of New Regulatory Framework

The new Egyptian administration has released a set of regulations to enhance the pharmaceutical business in Egypt, with the ambitious goal of increasing the industry is driving market expansion during forecast period. The Egyptian Law No. 151 of 2019, declares the establishment of the Egyptian Drug Authority (EDA) as its own entity and the Egyptian Authority for Unified Procurement, Medical Supply, and Technology Management as a separate economic unit. Egyptian Drug Authority (EDA) regulatory framework is governing the pharmaceutical industry in Egypt and has been completely restructured with the goal conceptualizing, developing, and strengthening the healthcare system and pharmaceutical industry in Egypt, thereby driving the growth of the Egypt Pharmaceutical market. Moreover, the new regulatory framework made it possible for the pharmaceutical industry in Egypt to recover quickly and effectively.

Delayed Governmental Approvals

The pharmaceutical industry in Egypt typically meets technical support miscommunication between governmental and pharmaceutical regulatory affairs, the gap between academia and industry, and regulatory, developmental, and manufacturing challenges beginning with product registration. It also includes delayed governmental approvals and marketing authorization for registered products, the high financial cost of the product registration process, and predatory or below-cost of approved products which in turn hamper the growth of the Egypt pharmaceutical market throughout the forecast period. However, additional regulatory issues based on 'win-win' approaches, quick production with real-time regulation, and outcome-based regulation, as well as regulatory activities such as regulatory analytics, regulatory intelligence and knowledge management, correspondence and commitment, authoring, programming, hyperlinking, translations, and data verification, are still to be resolved which limit the growth of the market.

Market Segmentation

Egypt Pharmaceutical Market is segmented on the basis of type, drug classification, mode of purchase, and distribution channel. Based on type, the market is further bifurcated into pharmaceutical drugs and biologics. The pharmaceutical drugs segment is further divided into gynecology drugs, respiratory drugs, dermatology drugs, analgesic drugs, oncology drugs, and others. Based on biologics the sub-segment is divided into Monoclonal Antibodies (MAbS), therapeutic proteins, and vaccines. Based on drug classification, the market is divided into branded drugs and generic drugs. On the basis of mode of purchase, the market is divided into prescription-based drugs and over-the-counter drugs. Based on distribution channel, the market is further divided into hospital pharmacies, retail pharmacies, and online pharmacies.

Market players

MDI Pharma, Merck & Co., Novartis AG, Pharco Pharmaceuticals, Roche Holding AG, Sanofi S.A, EVA Pharma, Orchidia Pharmaceutical Industries, GlaxoSmithKline, Tabuk Pharmaceuticals are the major drivers in the Egypt Pharmaceutical Market.

Report Scope:

In this report, the Egypt Pharmaceutical Market has been segmented into the following

Egypt Pharmaceutical Market By Type {Pharmaceutical Drugs (Gynecology Drugs, Respiratory Drugs, Dermatology Dr...

categories, in addition to the industry trends which have also been detailed below:

Egypt Pharmaceutical Market, By Type:

Pharmaceutical Drugs

Gynecology Drugs

Respiratory Drugs

Dermatology Drugs

Analgesic Drugs

Oncology Drugs

Others

Biologics

Monoclonal Antibodies (MAbS)

Therapeutic Proteins, Vaccines

Egypt Pharmaceutical Market, By Drug Classification

Branded Drugs

Generic Drugs

Egypt Pharmaceutical Market, By Mode of Purchase

Prescription-Based Drugs

Over-the-counter Drugs

Egypt Pharmaceutical Market, By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Egypt Pharmaceutical Market, By Region

Cairo

Alexandria

Giza Qalyubia

Port Said Suez

Rest of Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Egypt Pharmaceutical Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, and Trends

4. VOICE OF CUSTOMERS

5. EGYPT PHARMACEUTICAL MARKET OUTLOOK

- 5.1. Market Size & Forecast
 - 5.1.1. By Value & Volume
- 5.2. Market Share & Forecast
 - 5.2.1. By Type (Pharmaceutical Drugs v/s Biologics)
 - 5.2.1.1. By Pharmaceutical Drugs (Gynaecology Drugs, Respiratory Drugs, Dermatology Drugs, Analgesic Drugs, Oncology Drugs, Others)
 - 5.2.1.2. By Biologics (Monoclonal Antibodies (MAbS, Therapeutic Proteins, Vaccines)

- 5.2.2. By Drug Classification (Branded Drugs v/s Generic Drugs)
- 5.2.3. By Mode of Purchase (Prescription-Based Drugs v/s Over-the-counter Drugs)
- 5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- 5.2.5. By Region
- 5.2.6. By Company (2022)
- 5.3. Market Map

6. EGYPT BRANDED DRUGS MARKET OUTLOOK

- 6.1. Market Size & Forecast
 - 6.1.1. By Value
- 6.2. Market Share & Forecast
 - 6.2.1. By Type
 - 6.2.1.1. By Pharmaceutical Drugs
 - 6.2.1.2. By Biologics
 - 6.2.2. By Mode of Purchase
 - 6.2.3. By Distribution Channel

7. EGYPT GENERIC DRUGS MARKET OUTLOOK

- 7.1. Market Size & Forecast
 - 7.1.1. By Value
- 7.2. Market Share & Forecast
 - 7.2.1. By Type
 - 7.2.1.1. By Pharmaceutical Drugs
 - 7.2.1.2. By Biologics
 - 7.2.2. By Mode of Purchase
 - 7.2.3. By Distribution Channel

8. MARKET DYNAMICS

- 8.1. Drivers
- 8.2. Challenges

9. MARKET TRENDS & DEVELOPMENTS

10. POLICY & REGULATORY LANDSCAPE

11. EGYPT ECONOMIC PROFILE

12. COMPETITIVE LANDSCAPE

- 12.1. Amoun Pharmaceutical Company
- 12.2. EIPICO
- 12.3. Memphis Pharmaceutical and Chemical Industries
- 12.4. MDI Pharma
- 12.5. Merck & Co.
- 12.6. Novartis AG
- 12.7. Pharco Pharmaceuticals
- 12.8. Roche Holding AG
- 12.9. Sanofi S.A
- 12.10. EVA Pharma
- 12.11. Orchidia Pharmaceutical Industries
- 12.12. GlaxoSmithKline
- 12.13. Tabuk Pharmaceuticals

13. STRATEGIC RECOMMENDATIONS

I would like to order

Product name: Egypt Pharmaceutical Market By Type {Pharmaceutical Drugs (Gynecology Drugs, Respiratory Drugs, Dermatology Drugs, Analgesic Drugs, Oncology Drugs, Others) and Biologics), By Biologics (Monoclonal Antibodies (MAbS, Therapeutic Proteins, Vaccines)}, By Drug Classification (Branded Drugs v/s Generic Drugs), By Mode of Purchase (Prescription-Based Drugs v/s Over-the-counter Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, Competition, Forecast and Opportunities, 2028F

Product link: <https://marketpublishers.com/r/ECEB51BF6D50EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ECEB51BF6D50EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970